RSPR Pharma

RSPR Pharma was a Swedish private clinical-stage biotech developing novel oral therapies for respiratory diseases. Its lead compound, CRD007, was an oral mast cell inhibitor targeting patients with uncontrolled asthma despite standard therapy. The company initiated a randomized Phase II proof-of-concept trial involving up to 200 patients across multiple countries. Other pipeline assets included LY‑315996 for cardiovascular disease and pemirolast sodium for Duchenne muscular dystrophy. Major investors included HealthCap, Forbion Capital Partners, Novo Seeds, and Sunstone. As of May 2025 the company was listed as dissolved.